Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Active not recruiting 2Recruiting 1

Sponsor Class

NIH 3

Study Type

Observational 3Interventional 3

Sponsor

Cancer Type

Sarcoma 2Lymphoid 2

Conditions

Breast Neoplasms 1034Neoplasms 815Carcinoma, Non-Small-Cell Lung 799Prostatic Neoplasms 621Colorectal Neoplasms 529Lung Neoplasms 486Neoplasm Metastasis 434Multiple Myeloma 395Leukemia, Myeloid, Acute 391Ovarian Neoplasms 334Pancreatic Neoplasms 316Melanoma 297Squamous Cell Carcinoma of Head and Neck 268Recurrence 256Carcinoma, Hepatocellular 250Glioblastoma 238Brain Neoplasms 237Triple Negative Breast Neoplasms 213Carcinoma, Renal Cell 209Head and Neck Neoplasms 208Precursor Cell Lymphoblastic Leukemia-Lymphoma 201Lymphoma 201Stomach Neoplasms 197Endometrial Neoplasms 189Uterine Cervical Neoplasms 185Lymphoma, Non-Hodgkin 180Glioma 180Sarcoma 179Lymphoma, Large B-Cell, Diffuse 167Hematologic Neoplasms 162

Interventions

liposomal doxorubicin 2pomalidomide 1Zidovudine 1Vincristine 1Valganciclovir 1Sirolimus 1Rituximab 1Prednisone 1Interferon-alpha 1Granulocyte Colony-Stimulating Factor 1Filgrastim 1Etoposide 1Doxorubicin 1Cyclophosphamide 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Multi-centric Castleman's Disease × 90 days × Clear all
NCT02659930 2026-06-04

Pomalidomide in Combination With Liposomal Doxorubicin in People With Advanced or Refractory Kaposi Sarcoma

National Institutes of Health Clinical Center (CC)

Phase 1 Active not recruiting
62 enrolled
Sarcoma

Multi-centric Castleman's Disease, Acquired Immunodeficiency Syndrome, Sarcoma, Kaposi

NCT05907759 2026-06-02

Daratumumab for Relapsed/Refractory Primary Effusion Lymphoma, Plasmablastic Lymphoma, and Multicentric Castleman Disease

National Institutes of Health Clinical Center (CC)

Phase 2 Recruiting
28 enrolled
LymphoidSarcoma

Multi-centric Castleman's Disease, Lymphoma, Non-Hodgkin, Sarcoma, Kaposi, Lymphoma, Primary Effusion

NCT00092222 2026-06-01

Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity

National Institutes of Health Clinical Center (CC)

Phase 2 Active not recruiting
75 enrolled
Lymphoid

Multi-centric Castleman's Disease, Macular dystrophy, corneal type 1, Lymphadenopathy, Lymphoproliferative Disorders, Neoplasms, HIV Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡